One-year experience with latanoprostene bunod ophthalmic solution 0.024% in clinical practice: A retrospective observational study
Although high intolerable adverse effects including conjunctival hyperemia and eye irritation happened in the first month, remaining sixty percent of patients exhibited statistically significant additional IOP reductions in the replacement of other PGAs during 12 months of clinical use of LBN 0.024%.
Authors
- Siao-Pei Guo (ORCID: https://orcid.org/0000-0002-9069-061X)
- Jou-Chen Huang
- Si-Huei Lee (ORCID: https://orcid.org/0000-0002-0304-5461)
- Tsung-Jen Wang
- Chun-Mei Hsueh
- Chen-Hsin Tsai
Institutions
- Taipei Medical University Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-08-22
- DOI
- https://doi.org/10.1371/journal.pone.0307132
- Citations
- 3
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.62